Last reviewed · How we verify
0.5% Levobupivacaine
0.5% Levobupivacaine is a Small molecule drug developed by Chinese University of Hong Kong. It is currently FDA-approved. Also known as: Chirocaine, Peripheral nerve block, 0.5% Chirocaine.
0.5% Levobupivacaine, developed by the Chinese University of Hong Kong, is a marketed anesthetic with a key composition patent expiring in 2028. The drug's primary strength lies in its established market presence and the extended patent protection, which helps maintain competitive barriers. The primary risk is the patent expiry in 2028, which could lead to increased competition from generic versions.
At a glance
| Generic name | 0.5% Levobupivacaine |
|---|---|
| Also known as | Chirocaine, Peripheral nerve block, 0.5% Chirocaine |
| Sponsor | Chinese University of Hong Kong |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Comparison of Analgesic Efficacy of Intrathecal Levobupivacaine With and Without Oral Tizanidine in Lower Limb Surgeries: A Prospective Randomized Study (PHASE4)
- Efficacy of Scalp Block in Managing Post Subarachnoid Hemorrhage Headache in Critically Ill Patients. A Single Centre Randomized Controlled Trial (NA)
- Efficacy of Magnesium Sulfate as an Adjuvant in Erector Spinae Plane Block as an Anesthetic Post Operative After Modified Radical Mastectomy (EARLY_PHASE1)
- Comparative Study of the Effects of Two Local Anesthetics Administered Intrathecally: 0.5% Levobupivacaine and Ropivacaine 0.5% (PHASE4)
- Preoperative Use of Peripheral Nerve Blocks in Elderly Patients With Hip Fractures (PHASE4)
- ACU_Knee: Role of Acupuncture in Knee Prosthetic Surgery (NA)
- Comparison of Loco-regional Analgesic Techniques in Patients Undergoing Video Assisted Thoracoscopic Surgery (VATS) (NA)
- Non-opioid Anesthesia Based on Thoracic Paravertebral Block During Laparoscopic Sleeve Gastrectomy (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- 0.5% Levobupivacaine CI brief — competitive landscape report
- 0.5% Levobupivacaine updates RSS · CI watch RSS
- Chinese University of Hong Kong portfolio CI
Frequently asked questions about 0.5% Levobupivacaine
What is 0.5% Levobupivacaine?
Who makes 0.5% Levobupivacaine?
Is 0.5% Levobupivacaine also known as anything else?
What development phase is 0.5% Levobupivacaine in?
Related
- Manufacturer: Chinese University of Hong Kong — full pipeline
- Also known as: Chirocaine, Peripheral nerve block, 0.5% Chirocaine
- Compare: 0.5% Levobupivacaine vs similar drugs
- Pricing: 0.5% Levobupivacaine cost, discount & access